Seeking Alpha

Intercept shares go crazy, Galectin jumps

  • Galectin Therapeutics (GALT), which develops galectin inhibitors against NASH/liver fibrosis, jumps 17.5% following the storming success of Intercept Pharmaceuticals' (ICPT) beticholic acid in a trial.
  • Another company that operates in the space, La Jolla Pharmaceutical (LJPC), is +2.6%.
  • Intercept is up 245% at around $250, giving it a market cap of $4.9B. BMO has given the stock a price target of $270.
  • Despite the hoopla, it's worth noting that the company generates minimal revenue.
  • $ICPT on Twitter.
  • ETF: IBB
Comments (6)
  • out of the two $GALT & $LJPC which one is the next $ICPT???
    9 Jan, 11:48 AM Reply Like
  • I think $LJPC. The Backer Brothers are in $LJPC as well.
    9 Jan, 12:52 PM Reply Like
  • $TNXP is the next one to make the big move, fantastic board of directors, honestly best ive ever seen in a pharmaceutical + they're reformulating a drug thats been around for 30+ years, At a $80M market cap a move to say $2B is still 25x current price..

     

    ICTP is $5B fwiw so TNXP is 60x less so approval next october could be an equal boon
    9 Jan, 03:10 PM Reply Like
  • Actually, GALT jumped 59.29% (not 17.5%) on 49 times its average 10 day volume, trading over 6 million shares today.
    9 Jan, 09:19 PM Reply Like
  • There is another molecule which is much more promising than ICPT's, the GFT505 the company is a french company , GENFIT (code ALGFT) and is in direct competition with ICPT, The drug is also in Phase 2b (ending October 2014) and has received complete inocuity in October 2013. Its market cap is a mere 210 Million Euros.
    10 Jan, 01:20 AM Reply Like
  • Loving $LJPC at these levels!!! Adding and Holding Long because I am extremely BULLISH on this company in 2014!!!!
    10 Jan, 11:16 AM Reply Like
DJIA (DIA) S&P 500 (SPY)